Wolfe & Wine Co. is using a new software to dispatch meals to hospital workers as well as new meal prep customers. Getty Images

With an abundance of Houston restaurant and business closures spurred by the coronavirus pandemic, small company leaders are forced to develop resourceful solutions to keep afloat and compensate for slowed revenue.

Founder and chef of Houston-based Wolfe & Wine Co., Daniel Wolfe, has rejigged his social-focused business model to cater single-meal orders instead of large group orders.

Wolfe & Wine Co. is a full-service, chef-driven catering company, specializing in pop-up dinners paired with specially curated wines. Launched only a few short months ago in September 2019, Wolfe was looking forward to expanding his business across the Houston metroplex in 2020, one specially-catered social gathering at a time. His plans changed in March, when COVID-19 began to ingratiate itself in pockets of Houston.

"My business model thrives on events with more than 10 people, so we pivoted our focus to meal prep," Wolfe says.

Within 72 hours in March, Wolfe lost around $70,000 worth of revenue with the cancelation of all of his upcoming catering events, then feeling the first wave of economic and logistical impacts of COVID-19. However, Wolfe faced these hurdles with innovative and community-focused solutions that have already sustained his business and benefitted thousands of Houstonians whose lives have been affected by the coronavirus.

With the help of food service supplier Ben E. Keith Co. and cloud-based delivery management software company Dispatch Science, Wolfe & Wine Co. received the financial and technological sponsorship needed to provide single meals to his customers, and to donate meals to medical staff, including the entire Houston Methodist Emergency Room and ICU departments, and Houstonians in need.

"The dispatch software that we use is similar to what UPS, FedEx and Amazon use. When you order with us, you can track where your meal is in real time…That transparency separates us from [other meal prep companies]," Wolfe says.

Since producing single-order meal prep packages for his customers, Wolfe has noted that the two biggest challenges he has faced have been altering his recipes to accommodate single servings, and striving to maintain the same high-quality, personalized customer experience that he provides at his catering events.

In various industries, not only in Houston but across the globe, there will be elements of business that are forced to restructure, to accommodate the new economic and logistical boundaries brought upon by the COVID-19 pandemic.

"This virus is forcing people to innovate, forcing people stuck in their ways to change and adapt, or they'll fail," Wolfe says.

For the hospitality industry specifically, Wolfe foresees that restaurants' refined food takeout processes, along with the delivery of liquor, beer and wine, will play a huge role in their fiscal well-being after this health crisis subsides.

"Businesses that said 'we're not doing takeout' are now doing takeout because they don't have a choice," Wolfe says. "In the next few months, you're going to see a lot more offerings for takeout and delivery. You're going to see a lot more refined and better customer experiences for takeout, especially with millennials."

Sharpened takeout programs and alcohol delivery are projected to revolutionize the food and beverage industry, Wolfe says. In addition to enhanced technological components and takeout processes, community stewardship has been a main theme within the industry, Wolfe noted.

"The hospitality industry, nurses, grocery stores and others, those are the people carrying the country through this pandemic," Wolfe says. "You're not just some kid flipping a burger or stocking a box on a shelf."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.